Viewing nowPosigly Tablet 10 mg (Dapagliflozin Monohydrate Mixture)
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.

MFDS item code 202005321 · Approved 2020.07.23 · Insurance code 653806070
Treatment of type 2 diabetes mellitus, chronic heart failure, and chronic kidney disease
This medication is used to help control blood sugar in patients with type 2 diabetes and to reduce the risk of cardiovascular events in patients with cardiovascular disease or risk factors. It also lowers the risk of death due to cardiovascular disease and hospitalization or emergency visits due to heart failure in patients with chronic heart failure, and is administered in conjunction with other heart failure treatments. Additionally, in patients with chronic kidney disease, it helps maintain kidney health by reducing the risk of worsening kidney function, end-stage kidney disease, and cardiovascular-related mortality. This medication is used in conjunction with standard treatments for each condition to improve the overall health status of patients.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, including insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received drug treatment for diabetes, when used in combination with metformin, the recommended starting dose of this medicine is 5mg once daily or 10mg once daily. Chronic heart failure and chronic kidney disease The recommended dose of this medicine is 10 mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - eGFR less than 25 mL/min/1.73m2: Initiation of this medicine is not recommended in patients with chronic heart failure and chronic kidney disease. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. Swallow the tablet whole.
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.
This medication should not be used in patients with an allergy to the active ingredient or any additives. It should also not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication contains anhydrous lactose; thus, patients with hereditary problems such as lactase deficiency or galactose intolerance should not take it. This medication is not for patients undergoing dialysis. Caution is required for patients with reduced fluid volume or kidney dysfunction when using this medication. This medication can lower blood pressure and poses a risk of acute kidney injury, so kidney function and blood pressure status should be regularly monitored. Elderly patients or those taking diuretics are at higher risk for reduced fluid volume and hypotension, so they need to be monitored carefully. This medication contains Yellow No. 4 and Yellow No. 5 dyes, so patients allergic to these components should use it cautiously. During treatment with this medication, symptoms such as genital infections, urinary tract infections, hypoglycemia, reduced fluid volume, and diabetic ketoacidosis may occur, so symptoms should be observed closely. Diabetic ketoacidosis can occur even when blood sugar levels are within the normal range; thus, if symptoms like dehydration, vomiting, abdominal pain, or difficulty breathing manifest, immediate consultation with healthcare professionals is necessary. There is limited experience using this medication in patients with severely impaired liver function, so caution is required in liver disease patients. When used with blood sugar-lowering agents like insulin or sulfonylureas, the risk of hypoglycemia may increase, necessitating dosage adjustments. It is recommended that women who are pregnant or breastfeeding do not take this medication, and it should be discontinued immediately if pregnancy is confirmed. The safety and efficacy of this medication in pediatric patients have not been established, so it is not used in pediatric patients. In case of overdose, because there is no specific antidote, it is important to receive symptomatic treatment, and caution should be taken for symptoms of dehydration or hypotension. This medication does not significantly affect the ability to drive or operate machinery, but caution is necessary for possible hypoglycemia symptoms. Finally, this medication should be kept out of the reach of children and stored in its original container to maintain quality.
Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal gangrene, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, increased hematocrit, early treatment decrease in renal creatinine clearance, dyslipidemia, early treatment increase in blood creatinine, increased blood urea, weight loss, rash, angioedema, urosepsis, pyelonephritis, acute kidney injury, renal dysfunction, gastroesophageal reflux disease, epigastric pain, diverticulitis, bowel perforation, acute pancreatitis, chronic pancreatitis, hyperglycemia, sensory disturbances, cerebral infarction, nerve compression, weakness, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina pectoris, myocardial infarction, biliary stones, cholangitis, alcoholic cirrhosis, depression, suicide attempts, gastric adenocarcinoma, anaphylactic reaction, sensory loss, headache, dyspepsia, nausea, diarrhea, vomiting, urinary retention, increased alanine aminotransferase, increased aspartate aminotransferase, decreased appetite, next symptom, headache, nasopharyngitis, upper respiratory infection, edema, fever, foreign body sensation, facial swelling, facial pain, warmth, flu-like symptoms, vaginal discharge, menstrual irregularities, itching, hives, night sweats, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament strain, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyps, tinnitus
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect from air and moisture. The recommended storage temperature is between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's efficacy and safety.
Yellow, double-convex, diamond-shaped film-coated tablet
28 tablets/box [14 tablets/PTP x 2], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowDapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
AlboGen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.